GlySens Incorporated Granted New Patent, Expanding Portfolio for Glucose Sensor Technology
San Diego, CA – September 8, 2018 – GlySens® Incorporated today announced the United States Patent and Trademark Office has issued the company another new patent. GlySens has exclusive rights to the patented technology and adds it to its existing portfolio, bringing the company’s total to nine glucose sensor patents.
U.S. Patent 10,041,897 covers a foundational element of the sensor technology incorporated in the Long-Term, implantable, Eclipse® ICGM® System, which is intended to deliver the next generation of continuous glucose monitoring. The implantable sensor is designed to reside in the subcutaneous tissue, in a lower abdominal quadrant, for up to 1-year with no through the skin or on body components. This design will reduce the burden of diabetes devices by eliminating the stigma of externally worn components. “We know many people start CGM and want to use CGM but ultimately stop and don’t continue. We believe one reason for discontinuing is the need for adhesive patches and plastic components on your body, 24/7. We simply do not wish to compromise and believe CGM should be unobtrusive and easy to use and the ICGM System takes steps in that direction” said William H. Markle, President and CEO of GlySens Incorporated. The investigational device has been previously evaluated in multiple human trials and continues development with additional performance and feasibility studies forthcoming.
In the United States, more than 30 million adults and children have diabetes. The total economic cost of diabetes in 2017 was $327 billion. Diabetes devices are rapidly expanding the reach of technology to empower those individuals managing their disease. A fully implanted CGM sensor with minimal maintenance, could offer an unobtrusive tool for glucose management and integrate with additional technologies for improved health outcomes. The long-term, Eclipse® ICGM® System is designed to empower individuals by providing the information they need, while freeing them to live life on their own terms.
About GlySens Incorporated
GlySens Incorporated is a privately held corporation devoted to developing the world’s first unobtrusive, truly long-term continuous glucose monitoring system, intended to dramatically improve and simplify the lives of people with diabetes. The GlySens fully implanted sensor wirelessly communicates to an external receiver, designed to provide continuous, at-a-glance glucose reporting and alerts regarding hypo- and hyperglycemic glucose excursions. While other CGM approaches may require calibration multiple-times-per-day and demand continuous wearing of through-the-skin or skin-attached components, the calibration checks of the GlySens sensor are designed to be required only infrequently, freeing users from burdensome care and maintenance requirements. For people living with diabetes, the GlySens implantable continuous glucose monitoring system (the GlySens ICGM system) is intended to provide a means for easy, unobtrusive, worry-free glucose monitoring, and empower users by providing the information they need, while freeing them to live life on their own terms. “Live more, worry less.”
Eclipse, ICGM and GlySens are trademarks of GlySens Incorporated registered in the U.S. Patent and Trademark Office.
Caution – INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL LAW TO INVESTIGATIONAL USE.